Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 23c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
May 6, 2021 7:31 AM EDTEnrolling Patients in Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients
Today Announced Three-Part KOL Webinar Series on Its Portfolio of Investigational Targeted Hematology Therapies, Beginning May 2021
On Track to Achieve 2021 Milestones, Including Initiation of SY-1425 and SY-2101 Clinical Trials in 2H 2021 and Additional Dose-Escalation Data for SY-5609 in 3Q 2021
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:... More
